Once peptides have been received, it is imperative that they are kept cold and away from light
Commercially available GLP-1 support patches are typically applied for 8 hours
The clinical investigators specifically noted that "gastrointestinal adverse events were partially mitigated by the use of a lower starting dose." Starting at 1 mg, which is what the Phase 3 TRIUMPH trials use, provides even more tolerability protection
Retrieved from Bliddal, M., Nohmie, G., Damkier, P., et al
Retatrutide has a half-life of approximately six days, which supports once-weekly dosing
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial